ドライアイ治療薬市場：薬剤タイプ、製品形態、有効成分、作用機序、流通チャネル、ユーザープロファイル別-2025-2030年世界予測

ドライアイ治療薬市場は、2024年には48億6,000万米ドルとなり、2025年には51億8,000万米ドル、CAGR6.72%で成長し、2030年には71億9,000万米ドルに達すると予測されています。

ドライアイ治療薬市場は、最先端の研究、眼生理学の深い理解、拡大する患者層が一体となった高度なエコシステムへと進化しています。最近の技術的躍進と臨床ガイドラインの充実が、この進化を後押ししています。バイオテクノロジーと製薬製剤の進歩は、ドライアイ疾患の対症療法と根本的な原因の両方に対処する、より効果的な治療法への道を開いた。ドライアイという症状に対するヘルスケアの認知度が高まり、ドライアイの管理に精通した医療従事者が増えたことで、より効果的な治療法への関心が高まっています。

このダイナミックな市場は、もはや伝統的な治療法に限定されるものではないです。それどころか、新しい点眼薬や補助療法など、ドラッグデリバリーにおける技術革新の融合が、治療プロトコルを絶えず変化させています。その結果、メーカーや製薬会社は現在、有効性と患者の快適性のバランスを考慮した包括的な治療レジメンの開発に重点を置いています。科学的研究と実用的な臨床応用の統合は、この分野での投資と成長の新たな機会を生み出しています。

さらに、この市場の進化は、患者中心のアプローチがより個別化された治療につながるという、世界のヘルスケア産業における幅広い動向を反映しています。強化された診断ツールとデジタル・モニタリング・システムは、現在、個々の患者のニーズに合わせた治療を行うために使用されており、各治療コースが綿密なデータ主導の洞察に裏打ちされたものであることを保証しています。このような個別化治療と高度な治療オプションの統合は、ドライアイ症状の管理に有望な未来を意味します。

ドライアイ治療薬市場の変革

過去10年間、ドライアイ治療薬の状況は、臨床応用と戦略的市場ポジショニングの両方を再定義するような変革的な変化を遂げてきました。こうした変化の主な要因は、エビデンスに裏打ちされた治療への注目の高まり、長期的な眼症状の緩和に対する要求、患者のQOL向上への献身です。ドラッグデリバリーシステムの革新は、治療薬がより高い精度で標的組織に到達し、副作用を最小限に抑えながら製剤が意図したとおりに作用することを保証することを意味します。

伝統的な方法論と現代的な技術革新を統合した、学際的な治療アプローチへの動きは明らかです。製薬会社は、新規治療薬の試験と承認を迅速化するために、適応性のある臨床試験デザインを採用しています。規制環境は徐々に革新的な試験結果を受け入れるようになり、それによって開発と実施の迅速なサイクルが促進されています。

既存企業も新興企業も研究開発に投資する中、患者のエンゲージメントとアドヒアランスを高めるためのデジタルモニタリングツールの利用が、こうした進歩を補完しています。テクノロジーは、患者中心の戦略を洗練させ、診断とフォローアップケアのプロセスを強化し、最終的に市場成長を促進する上で重要な役割を果たしています。市場の進化は、業界のリーダーたちに絶え間ない技術革新を促し続け、有効性と安全性の両方が製品設計の最優先事項であり続けるようにしています。

さらに、学界、バイオテクノロジー企業、製薬大手間の提携が、研究の新たなベンチマークを設定しつつあります。こうした提携は、科学的知識の基盤を拡大するだけでなく、研究室での知見から臨床応用へのスムーズな移行を促しています。現在進行中の臨床試験や実臨床でのエビデンスが蓄積されるにつれ、こうした協力体制はドライアイ治療における治療パラダイムを再定義するのに十分な勢いを生み出しています。

市場進化を形成する主要セグメンテーションの洞察

ドライアイ治療薬市場のセグメンテーションは、その構造と将来の方向性に関する重要な洞察を提供します。薬剤の種類に基づく分析では、市販薬と処方薬の2つの選択肢に焦点が当てられていることが明らかになり、入手のしやすさと個別化された治療介入の必要性のバランスが強調されています。製品形態を調べると、点眼薬、まぶた拭き、ジェル、軟膏、スプレーなど多様なポートフォリオがあり、それぞれが特定の臨床要件や患者の嗜好に対応していることがわかる。

有効成分に基づいてさらに分析すると、さらに微妙な理解が得られます。カルボキシメチルセルロースのような成分は潤滑性を高め、シクロスポリンやリフィテグラストのような成分は炎症に対処する強力な免疫調節剤として機能します。ポリエチレングリコールもまた、治療レジメンをサポートするユニークな特性で認められています。作用機序を含む階層的なセグメンテーションも同様に洞察に富んでいます。この市場は、抗炎症剤、免疫調節剤、潤滑剤、分泌促進剤を統合することで区別されています。このことは、この疾患の複雑性を強調するだけでなく、多面的な治療戦略を適用することの重要性を強調しています。

流通チャネルの調査では、市場をさらに病院薬局、オンライン薬局とeコマース・プラットフォーム、伝統的な小売薬局に分類しました。これらのチャネルはそれぞれ、市場力学と消費者のアクセスに独自の貢献をしています。さらに、成人、老年、小児を考慮したユーザープロファイルのセグメンテーションにより、多様な年齢層に合わせた治療法の必要性が浮き彫りになり、特定の人口統計学的ニーズを確実に満たすことができます。この包括的なセグメンテーションの枠組みにより、利害関係者は世界のドライアイ患者コミュニティの多種多様な要求に直接対応する戦略を開発・展開することができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でドライアイ症候群の罹患率が増加
    • 目の健康と積極的なセルフケア行動に関する消費者の意識の高まり
    • ヘルスケアインフラの拡大と眼科サービスへのアクセス改善
  • 抑制要因
    • 患者のコンプライアンスと長期的な有効性の問題
  • 機会
    • イノベーションサイクルを加速させるための研究開発におけるパートナーシップの強化
    • ドライアイ治療薬における世界アクセスとパーソナライズされたソリューションのためのeコマースプラットフォームの拡張
  • 課題
    • さまざまな地域における厳格な規制遵守
• 市場セグメンテーション分析
  • 製品形態：刺激物質を除去し、患者の炎症を軽減するためのまぶた拭き取りシートの採用
  • 流通チャネル：規制上の課題に対処し、拡大する消費者の需要を満たすために、オンライン薬局が好まれる傾向が高まっています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 ドライアイ治療薬市場薬剤の種類別

• 市販薬
• 処方薬

第7章 ドライアイ治療薬市場：製品形態別

• 目薬
• まぶた拭き
• ゲル
• 軟膏
• スプレー

第8章 ドライアイ治療薬市場有効成分別

• カルボキシメチルセルロース
• シクロスポリン
• リフィテグラスト
• ポリエチレングリコール

第9章 ドライアイ治療薬市場作用機序別

• 抗炎症剤
• 免疫調節薬
• 潤滑剤
• 分泌促進剤

第10章 ドライアイ治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局/Eコマースプラットフォーム
• 小売薬局

第11章 ドライアイ治療薬市場ユーザープロファイル別

• 大人
• 老年医学
• 小児科

第12章 南北アメリカのドライアイ治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域のドライアイ治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのドライアイ治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Alcon Inc.
• Astellas Pharma Inc.
• Bausch+Lomb Corporation
• EyeGate Pharmaceuticals, Inc.
• Harrow Health, Inc.
• Johnson & Johnson Services, Inc.
• Kala Pharmaceuticals, Inc.
• Kowa Company, Ltd.
• Laboratorios Sophia S.A. De C.V.
• Merck & Co., Inc.
• Mitotech S.A.
• Nicox S.A.
• Novartis AG
• Ocugen, Inc.
• Ocular Therapeutix, Inc.
• Optix Pharmaceuticals, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Perrigo Company plc
• Pfizer Inc.
• Rohto Pharmaceutical Co., Ltd.
• Santen Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Viatris Inc.
• Wockhardt Ltd. by Dr. Reddy's Laboratories

LIST OF FIGURES

• FIGURE 1. DRY EYE MEDICATION MARKET MULTI-CURRENCY
• FIGURE 2. DRY EYE MEDICATION MARKET MULTI-LANGUAGE
• FIGURE 3. DRY EYE MEDICATION MARKET RESEARCH PROCESS
• FIGURE 4. DRY EYE MEDICATION MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. DRY EYE MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. DRY EYE MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DRY EYE MEDICATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DRY EYE MEDICATION MARKET DYNAMICS
• TABLE 7. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OVER-THE-COUNTER MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRESCRIPTION MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE LID WIPES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY CARBOXYMETHYLCELLULOSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LIFITEGRAST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY POLYETHYLENE GLYCOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LUBRICATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SECRETAGOGUES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ONLINE PHARMACIES/E-COMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 53. CANADA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. CANADA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 55. CANADA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 56. CANADA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 57. CANADA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. CANADA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 85. CHINA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. CHINA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 87. CHINA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 88. CHINA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 89. CHINA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. CHINA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 91. INDIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. INDIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 93. INDIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 94. INDIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 95. INDIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. INDIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 194. ITALY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 195. ITALY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 196. ITALY DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 197. ITALY DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 198. ITALY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. ITALY DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 218. POLAND DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 219. POLAND DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 220. POLAND DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 221. POLAND DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 222. POLAND DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. POLAND DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 224. QATAR DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 225. QATAR DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 226. QATAR DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 227. QATAR DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 228. QATAR DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. QATAR DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
• TABLE 284. DRY EYE MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 285. DRY EYE MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024

The Dry Eye Medication Market was valued at USD 4.86 billion in 2024 and is projected to grow to USD 5.18 billion in 2025, with a CAGR of 6.72%, reaching USD 7.19 billion by 2030.

The dry eye medication market has evolved into a sophisticated ecosystem that brings together cutting-edge research, a deeper understanding of ocular physiology, and an expanding patient demographic. Recent technological breakthroughs combined with enhanced clinical guidelines have catalyzed this evolution. Advances in biotechnology and pharmaceutical formulations have paved the way for more effective therapies that address both the symptomatic and underlying causes of dry eye disease. Increasing awareness of the condition and a growing base of healthcare professionals trained in its management have driven further interest in improved therapeutic options.

This dynamic market is no longer confined to traditional remedies. Instead, a blend of innovation in drug deliveries, such as novel eye drops and adjunct therapies, continuously reshapes treatment protocols. As a result, manufacturers and pharmaceutical companies are now placing an emphasis on the development of comprehensive treatment regimens that balance efficacy with patient comfort. The integration of scientific research with practical clinical applications has created new opportunities for investment and growth within the sector.

Furthermore, the market's evolution reflects wider trends in the global healthcare industry where patient-centric approaches are leading to more personalized therapy. Enhanced diagnostic tools and digital monitoring systems are now being used to tailor treatments to individual patient needs, ensuring that each therapy course is backed by meticulous data-driven insights. This integration of personalized care and advanced therapeutic options signifies a promising future for the management of dry eye conditions.

Transformative Shifts in the Dry Eye Medication Landscape

Over the past decade, the dry eye medication landscape has undergone transformative shifts that have redefined both clinical applications and strategic market positioning. These changes are primarily driven by an increased focus on evidence-backed treatments, a demand for prolonged relief, and a dedication to enhancing patient quality of life. Innovation in drug delivery systems now means that therapies reach the target tissues with improved precision, ensuring that formulations work as intended, while minimizing side effects.

There is a clear movement towards a multi-disciplinary treatment approach that encompasses integration between traditional methodologies and modern innovation. Pharmaceutical companies have embraced adaptive clinical trial designs to expedite the testing and approval of novel therapies. The regulatory environment has gradually become more accommodating to innovative trial results, thereby fostering a rapid cycle of development and implementation.

As both established and emerging companies invest in research and development, the use of digital monitoring tools to increase patient engagement and adherence has complemented these advancements. Technology has played a crucial role in refining patient-centric strategies, enhancing the diagnosis and follow-up care process, and ultimately driving market growth. The market's evolution continues to prompt industry leaders to innovate relentlessly, ensuring that both efficacy and safety remain top priorities in product design.

Moreover, partnerships between academia, biotechnology firms, and pharmaceutical giants are setting new benchmarks for research. These alliances are not only expanding the scientific knowledge base but are also facilitating a smoother transition from laboratory findings to clinical application. As ongoing clinical trials and real-world evidence accumulate, this collaborative spirit is generating sufficient momentum to redefine treatment paradigms in the management of dry eye disease.

Key Segmentation Insights Shaping Market Evolution

The segmentation of the dry eye medication market offers critical insights into its structure and future direction. Analysis based on drug type reveals a dual focus between over-the-counter medications and prescription options, highlighting a balance between accessibility and the need for tailored therapeutic interventions. An examination of the product form reveals a diverse portfolio that includes eye drops, eye lid wipes, gels, ointments, and sprays, each addressing specific clinical requirements and patient preferences.

Further analysis based on active ingredients provides an even more nuanced understanding. Ingredients such as carboxymethylcellulose offer enhanced lubrication, while others like cyclosporine and lifitegrast serve as potent immunomodulatory agents addressing inflammation. Polyethylene glycol is also recognized for its unique properties that support the therapeutic regimen. The layered segmentation that includes the mode of action is equally insightful. The market distinguishes itself by integrating anti-inflammatory agents, immunomodulatory agents, lubricating agents, and secretagogues. This not only underscores the complexity of the disease but underlines the importance of applying multifaceted treatment strategies.

The survey of the distribution channel further stratifies the market into hospital pharmacies, online pharmacies and e-commerce platforms, and traditional retail pharmacies. Each of these channels contributes uniquely to market dynamics and consumer access. Additionally, the user profile segmentation, which considers adults, geriatrics, and pediatrics, highlights the need for therapies that are tailor-made for diverse age groups, ensuring that specific demographic needs are met. This comprehensive segmentation framework enables stakeholders to develop and deploy strategies that directly address the multifarious requirements of the global dry eye patient community.

Based on Drug Type, market is studied across Over-The-Counter Medication and Prescription Medication.

Based on Product Form, market is studied across Eye Drops, Eye Lid Wipes, Gels, Ointments, and Sprays.

Based on Active Ingredient, market is studied across Carboxymethylcellulose, Cyclosporine, Lifitegrast, and Polyethylene Glycol.

Based on Mode of Action, market is studied across Anti-Inflammatory Agents, Immunomodulatory Agents, Lubricating Agents, and Secretagogues.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies/E-commerce Platforms, and Retail Pharmacies.

Based on User Profile, market is studied across Adults, Geriatrics, and Pediatrics.

Critical Regional Insights Across Key Markets

A detailed regional analysis reveals significant geographic disparities in market activity and patient needs. In the Americas, a proactive approach to healthcare combined with robust insurance frameworks has spurred widespread acceptance of innovative therapies. Clinical trial activity and consumer awareness in this region have reinforced the importance of treatment customization, encouraging ongoing investment in pharmaceutical research.

In the combined region of Europe, Middle East and Africa, diverse economic realities and heterogeneous healthcare systems challenge manufacturers to adapt their strategies to local demands. While regulatory frameworks in Europe promote innovation, emerging markets in the Middle East and Africa are gradually aligning with global standards. The need for affordable yet effective treatments is driving cost-efficient innovations, thereby opening new economic avenues and niche segments that are poised for growth.

The Asia-Pacific region represents a rapidly evolving market where large populations, an increasing prevalence of dry eye conditions, and rising disposable incomes are coalescing to reshape market dynamics. Growing awareness and improved access to healthcare have generated demand for specialized therapeutic solutions. Innovations are being rapidly adopted as local manufacturers seek to address regional patient needs by aligning their products with both traditional and modern medicinal approaches. Each region's unique characteristics and requirements highlight an intricate balance between innovation, patient education, and the need for cost-effective solutions.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Company-Level Strategies Driving Competitive Advantages

The competitive landscape in the dry eye medication market is both diverse and dynamic, with a large number of influential players each carving out a niche in this evolving field. Major pharmaceutical companies like AbbVie Inc., Alcon Inc. and Astellas Pharma Inc. have strategically positioned themselves through extensive research and robust clinical portfolios, setting high benchmarks for quality and efficacy. Equally prominent, industry stalwarts such as Bausch + Lomb Corporation have continually leveraged their experience to stay ahead in an ever-changing market.

Innovative smaller companies including EyeGate Pharmaceuticals, Inc. and Harrow Health, Inc. are redefining segments through niche product offerings and agile market strategies. Additionally, the strong industry presence maintained by Johnson & Johnson Services, Inc. further accentuates a competitive landscape that thrives on both innovation and scale. Emerging players such as Kala Pharmaceuticals, Inc. and the multifaceted approach of Kowa Company, Ltd. and Laboratorios Sophia S.A. De C.V. contribute to an environment where strategic partnerships and relentless product development are the norms.

Other well-known entities, notably Merck & Co., Inc. and Mitotech S.A., have committed significant resources to research endeavors aimed at addressing unmet clinical needs. Companies like Nicox S.A. and Novartis AG exemplify the balance between traditional pharmaceutical expertise and modern therapeutic innovation. The market is further enriched by contributions from Ocugen, Inc., Ocular Therapeutix, Inc., and Optix Pharmaceuticals, Inc. which offer distinct treatment modalities. In addition, industry giants such as Otsuka Pharmaceutical Co., Ltd., Perrigo Company plc, and Pfizer Inc. have deepened their focus on the development of dry eye medications through targeted research.

The innovative initiatives by Rohto Pharmaceutical Co., Ltd. and Santen Pharmaceutical Co., Ltd., along with the expansive reach of Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited, continue to redefine competitive frameworks. Other notable players such as Viatris Inc. and Wockhardt Ltd. bolster a competitive landscape that is marked by diversity and continuous innovation. Collectively, these companies illustrate a market where strategic research, expansive distribution networks, and a commitment to product excellence drive the future of dry eye medications.

The report delves into recent significant developments in the Dry Eye Medication Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Astellas Pharma Inc., Bausch + Lomb Corporation, EyeGate Pharmaceuticals, Inc., Harrow Health, Inc., Johnson & Johnson Services, Inc., Kala Pharmaceuticals, Inc., Kowa Company, Ltd., Laboratorios Sophia S.A. De C.V., Merck & Co., Inc., Mitotech S.A., Nicox S.A., Novartis AG, Ocugen, Inc., Ocular Therapeutix, Inc., Optix Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Perrigo Company plc, Pfizer Inc., Rohto Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Viatris Inc., and Wockhardt Ltd. by Dr. Reddy's Laboratories. Actionable Recommendations for Industry Leaders in Dry Eye Therapy

For industry leaders within the dry eye medication market, strategic decision-making is essential to remain competitive and meet the emerging needs of patients. Leaders should consider investing in advanced research initiatives that target both the symptomatic and underlying causes of dry eye disease. A robust commitment to innovation-encompassing not only novel molecules but also breakthrough delivery systems-will be critical in meeting evolving patient expectations.

Optimizing clinical trial frameworks should also remain a priority. By adopting adaptive clinical trials and leveraging digital health technologies for patient monitoring and data collection, companies can accelerate the time-to-market for new formulations. Regulatory harmonization across key markets is another aspect that can streamline the introduction of new therapies. Establishing collaborations with leading academic institutions and technology firms can further accelerate the pace at which innovations are brought to market.

In addition, tailoring treatments to meet the specific needs of diverse patient segments is of paramount importance. This involves a comprehensive understanding of division by drug type, with formulations that range in their application from over-the-counter solutions to prescription-based treatments. Emphasizing personalized patient care means investing in targeted therapies that consider both product form and active ingredient efficacy. Equally, integration of mode of action insights into product development strategies-incorporating mechanisms such as anti-inflammatory and immunomodulatory effects-can lead to more holistic treatment offerings.

Distribution efficiency is another critical area. Ensuring that products are readily available across hospital pharmacies, online platforms, and retail outlets will foster greater accessibility for patients. In parallel, aligning production strategies with the latest shifts in user profiles-catering to adults, geriatrics, and pediatrics-will be essential for long-term market growth. By embracing technological advancements, fostering partnerships, and committing to patient-centric solutions, industry leaders can harness emerging opportunities and mitigate existing challenges, thus reinforcing their competitive posture in an increasingly dynamic marketplace.

Conclusive Insights on Market Dynamics

In summary, the current landscape of dry eye medication is marked by both impressive innovation and increasing competition. A detailed examination of the market reveals persistent advancements in drug technology, shifts in regulatory standards, and diversification of therapeutic options. Through deliberate segmentation analysis, it is evident that a multifaceted approach-one that considers drug type, product formulation, and active ingredients-drives the development of more effective treatment regimens. Furthermore, evaluating the roles of mode of action, distribution channels, and user profiles provides a comprehensive framework that informs both product development and market strategy.

Industry players must remain vigilant in their pursuit of excellence by adopting agile approaches and aligning their research and development with emerging market trends. The integration of precision medicine, digital health, and robust data analytics stands as a testament to the potential for meaningful transformation in the sector. As market dynamics continue to evolve, companies that are both innovative and responsive to change will be best positioned to capture a larger share of the global market while improving overall patient outcomes.

This advanced understanding of market segmentation, regional dynamics, and competitive strategies ultimately forms the groundwork for strategic growth and sustainable competitive advantage. Embracing these insights will empower the industry to address current challenges and seize the multitude of opportunities that lie ahead.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of dry eye syndrome globally
    • 5.1.1.2. Rising consumer awareness about ocular health and proactive self-care behaviors
    • 5.1.1.3. Expanding healthcare infrastructure and improved access to ophthalmic services
  • 5.1.2. Restraints
    • 5.1.2.1. Patient compliance and long-term efficacy issues
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising partnerships in research and development to enable faster innovation cycles
    • 5.1.3.2. Expansion of e-commerce platform for global access and personalized solutions in the dry eye medication
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory compliances across different region
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Forms: Adoption of eye lid wipes to remove irritants and reducing inflammation in patients
  • 5.2.2. Distribution Channel: Growing preference for online pharmacies to address regulatory challenges and meet expanding consumer demands
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dry Eye Medication Market, by Drug Type

• 6.1. Introduction
• 6.2. Over-The-Counter Medication
• 6.3. Prescription Medication

7. Dry Eye Medication Market, by Product Form

• 7.1. Introduction
• 7.2. Eye Drops
• 7.3. Eye Lid Wipes
• 7.4. Gels
• 7.5. Ointments
• 7.6. Sprays

8. Dry Eye Medication Market, by Active Ingredient

• 8.1. Introduction
• 8.2. Carboxymethylcellulose
• 8.3. Cyclosporine
• 8.4. Lifitegrast
• 8.5. Polyethylene Glycol

9. Dry Eye Medication Market, by Mode of Action

• 9.1. Introduction
• 9.2. Anti-Inflammatory Agents
• 9.3. Immunomodulatory Agents
• 9.4. Lubricating Agents
• 9.5. Secretagogues

10. Dry Eye Medication Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies/E-commerce Platforms
• 10.4. Retail Pharmacies

11. Dry Eye Medication Market, by User Profile

• 11.1. Introduction
• 11.2. Adults
• 11.3. Geriatrics
• 11.4. Pediatrics

12. Americas Dry Eye Medication Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Dry Eye Medication Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Dry Eye Medication Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Ocumension entered into an agreement with Alcon to expand China's dry eye treatment portfolio
  • 15.3.2. Novaliq and Laboratoires Thea partner to launch Vevizye in Europe
  • 15.3.3. Nordic Pharma launch LACRIFILL Canalicular gel for dry eye therapy
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alcon Inc.
• 3. Astellas Pharma Inc.
• 4. Bausch + Lomb Corporation
• 5. EyeGate Pharmaceuticals, Inc.
• 6. Harrow Health, Inc.
• 7. Johnson & Johnson Services, Inc.
• 8. Kala Pharmaceuticals, Inc.
• 9. Kowa Company, Ltd.
• 10. Laboratorios Sophia S.A. De C.V.
• 11. Merck & Co., Inc.
• 12. Mitotech S.A.
• 13. Nicox S.A.
• 14. Novartis AG
• 15. Ocugen, Inc.
• 16. Ocular Therapeutix, Inc.
• 17. Optix Pharmaceuticals, Inc.
• 18. Otsuka Pharmaceutical Co., Ltd.
• 19. Perrigo Company plc
• 20. Pfizer Inc.
• 21. Rohto Pharmaceutical Co., Ltd.
• 22. Santen Pharmaceutical Co., Ltd.
• 23. Sun Pharmaceutical Industries Ltd.
• 24. Takeda Pharmaceutical Company Limited
• 25. Viatris Inc.
• 26. Wockhardt Ltd. by Dr. Reddy's Laboratories